ArticleJournal of hematology & oncology2018
A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.
Jianbiao Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papercites it